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Abstract
Background: An optimal inhalation flow pattern is essential for effective use of a dry powder inhaler (DPI). We
wondered whether DPI instructors inhale from a DPI with an appropriate pattern, and if not, whether self-training
with visual feedback is effective.
Methods: Subjects were 14 pharmacists regularly engaged in instruction in DPI use. A newly designed handy
inhalation flow visualizer (Visual Trainer: VT) was used to assess inhalation profiles and to assist in self-training.
With a peak inhalation flow rate (PIFR) > 50 L/min, time reaching PIFR (TPF) < 0.4 s, inhalation volume (VI) > 1 L,
and flow at 0.3 s after the onset of inhalation (F0.3) > 50 L/min, the pattern was considered optimal.
Results: Using Diskus or Turbuhaler 12 and 10 subjects respectively inhaled with a suitable PIFR. Those with a
satisfactory F0.3 were 10 and 7 respectively. The TPF was short enough in only 1 and 2 respectively. All 14 subjects
inhaled deeply (VI) through Diskus, and 10 did so through Turbuhaler. In the self-training session, only 3 subjects
satisfied all three variables at the first trial, while 2 or 3 trials were required in other subjects. Among the three
variables, optimal TPF was the most difficult to attain. Once a satisfactory inhalation pattern was achieved using
one DPI, eleven out of 12 subjects inhaled with a satisfactory pattern through the other DPI.
Conclusion: Visualization of the inhalation flow pattern facilitates the learning of proper inhalation technique
through a DPI.
Keywords: Dry powder inhaler, Instruction, Inhalation flow profile, Self-training
Background
Inhalation with an optimal flow pattern is mandatory for
effective use of dry powder inhalers (DPIs). The ISAM
(International Society of Aerosol in Medicine)/ERS
(European Respiratory Society) task force encourages in-
halation with different flow patterns using reservoir/blis-
ter-type or capsule-type DPIs [1]. However, convenient
devices depicting inhaled flow pattern are currently un-
available. Concerning this issue, we previously reported
a low-cost and handy inhalation profile analyzer [2]
which displays a trajectory of the inhaled flow through
the DPI, and some parameters such as peak inhaled flow
rate (PIFR), time reaching the PIFR (TPF), and inhaled
volume (VI) are also displayed. Using this device named
a Visual Trainer, we found that many patients who were
currently treated with a DPI did not inhale with a suit-
able flow pattern [2]. We then wondered whether DPI
instructors themselves inhaled with an ideal inhalation
pattern since they also were unaware of their inhalation
flow profiles through the DPI. Therefore, as the first
purpose of the present study using the Visual Trainer,
we assessed DPI inhalation profiles of pharmacists regu-
larly engaged in instruction in DPI use. Pharmacists are
largely responsible for DPI instruction in Japan. If they
did not inhale with an appropriate flow pattern, as the
second purpose, we assessed the effectiveness of visual
feedback using the Visual Trainer for self-training.
Methods
This study was permitted by the Human Ethics Commit-
tee of Shonan Fujisawa Tokushukai Hospital (approval
number 14–019). This study was registered in University
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Hospital Medical Information Network-Clinical Trial
Registry (April 24, 2013, ID: UMIN 000023136). Figure 1
shows the appearance of the Visual Trainer. Detailed
descriptions are shown elsewhere [2]. In brief, it is
12.5 × 8.0 × 3.5 cm in size and 300 g (including batteries)
in weight. The cost of its parts is approximately $100.
This system continuously measures pressure in the
mouthpiece of a DPI (Paw) through a fine plastic tube.
The Paw signals are converted to digital ones with a 10
bits A to D converter, and then processed by a micro-
computer. Sampling rates are each 10 ms for 0–1.27 s,
20 ms for 1.27–2.56 s, and 50 ms for 2.56–5.76 s. Inhal-
ation flow rate is calculated with the equation, flow =
constant × Paw
0.5, and is continuously displayed on a
GLCD (graphic liquid cell display). The PIFR, TPF, and
VI are calculated and also displayed on the GLCD. The
Paw data can be stored on an SD-card for later analysis.
Before conducting the human study, we confirmed the
accuracy of the Visual Trainer. In this experiment,
Diskus was placed in an airtight box as shown in Fig. 2a
and an inhalation simulator inhaled several times.
Pressure in the mouthpiece and airflow at the inlet of
the airtight box were continuously measured. Airflow
was measured with a pneumotachometer (TV-112 T,
Nihon Kohden, Tokyo, Japan).
The subjects were 14 pharmacists working in Shonan
Fujisawa Tokushukai Hospital. They participated volun-
tarily in the study after signing an informed consent. All
were engaged in DPI instruction to patients using In-
checks. Figure 3 shows the protocol for the study. The
study consisted of 2 parts. On the first day, the subjects
inhaled 3 times from both Diskus (DPI for Adair or
Fig. 1 Appearance of the visual trainer
Fig. 2 Accuracy of the Visual Trainer. a: Inhalation flow was
measured simultaneously using both the square root of airway
pressure (Paw) and a pneumotachometer while the DPI was placed
in an airtight box. b: Results of 7 consecutive inhalations from Diskus
with different flow rates
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Advair) and from Turbuhaler (DPI for Symbicort outside
of the US) using depleted devices devoid of active drug,
with a flow pattern which they believed to be optimal.
When one subject began with Diskus the next subject of
the group began with Turbuhaler. In this study, one
researcher collected data from all of the subjects using a
single Visual Trainer. The recorded data was later ana-
lyzed using Microsoft Excel and StatView 5.0 (SAS insti-
tute, Australia). Data differences of < 0.05 using a
Wilcoxon single-ranked test were considered significant.
The second study was conducted 2 weeks later. Only
13 of the 14 pharmacists participated in the study
because one subject had already achieved an acceptable
inhalation profile. We described the optimal inspiratory
flow pattern proposed by the ISAM/ERS task force [1].
Then, without a training session, twelve subjects began
self-training for a proper DPI inhalation using Visual
Trainers. They repeated inhalations until reaching all the
following 3 parameters; PIFR > 50 L/min, TPF < 0.4 s, VI >
1.0 L. We did not direct which DPI device was to be
used initially (1st session). In this study 5 visual trainers
were distributed among 13 subjects. This enabled the
subjects to complete each trial at intermission between
their pharmacy duties.
Results
Figure 2b shows the results of 7 consecutive inhalations
from Diskus with different flow rates with the time to
reach the peak inhalation flow at 0.5 s. The abscissa is
output from the penumotachmeter and the ordinate is
flow rate calculated from airway pressure, ie, output
from the Visual Trainer. There was good correlation be-
tween the two outputs, confirming the accuracy of the
Visual Trainer.
There were some inter-subject and inter-trial varia-
tions in inhaled flow patterns. Among them, a pattern
shown in Fig. 4 was most frequently observed. This
pattern was recorded while the subject inhaled through
Diskus, and a similar pattern was observed in this
subject while inhaling through Turbuhaler. This pat-
tern was classified as trapezoid in the previous study
[3]. It was characterized by the following variables;
PIFR 77.5 L/min, TPF 0.76 s, VI 1.57 L and F0.3
57.6 L/min, suggesting that the subject inhaled deeply
and strongly with rapid rise in flow.
Figure 5 shows PIFR, F0.3, TPF, and VI of individual sub-
jects in the first study. The gray lines represent thresholds
for each parameter. Their validity will be described later.
It can be seen that many subjects inhaled forcefully (PIFR)
and deeply (VI). In many subjects, peak flow did not ap-
pear during early inhalation (TPF), but F0.3 was close to
PIFR. Exact values and statistical significance of Fig. 4 are
listed in Table 1. It will be recognized that the subjects in-
haled more deeply (VI), more rapidly (F0.3), and with sig-
nificantly more strength (PIFR),using Diskus compared
with Turbuhaler. TPF in the two groups tended to be long
and no significant difference was found. Using Diskus 12
subjects inhaled with a suitable PIFR as did 10 using
Fig. 3 Study protocol
Fig. 4 An example of flow trajectory while a subject inhaled through Diskus. a: An optimal pattern [2]. b: Most frequently observed pattern
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Turbuhaler. All 14 subjects inhaled deeply (VI >1.0 L)
using Diskus and 10 did so using Turbuhaler. The time to
reach PIFR was less than 0.4 s in only 1 subject (Diskus)
and 2 subjects (Turbuhaler). Flow rate at the early phase
of inhalation (F0.3) was satisfactory in 10 subjects with Dis-
kus use, and 7 subjects with Turbuhaler use. There was
only one subject who reached all the thresholds in both
Diskus and Turbuhaler trials.
In the second study, all the subjects fulfilled the criteria
after a few self-training attempts. Figure 6 shows the num-
ber of training trials needed for subjects to fulfill the cri-
teria for the optimal inhalation pattern. Since TPFs
decreased remarkably after self-training, i.e., median TPF
0.34 s for Diskus and 0.31 s for Turbuhaler, F0.3s were al-
most the same as PIFR, and thus F0.3s are not shown in
Fig. 6. Ten subjects chose Diskus in the first session, and
the remaining subjects chose Turbuhaler first. Panel A
shows subject numbers who fulfilled all three criteria at
each trial. In using the initially selected DPI (1st session),
only 3 subjects fulfilled all three criteria at the first trial. In
most subjects 2 or 3 trials were necessary to fulfill the cri-
teria. In contrast, in the training using the second selected
DPI (2nd session), eleven out of 12 subjects reached the
three thresholds on the first trial. Panel B-D show trial
numbers to achieve individual parameters. In panels B
and D, it can be seen that most of the subjects inhaled
with a suitable PIFR and VI at the first trial of either the
first or second session. In contrast, an adequate TPF was
difficult to attain at the first study of the first session while
many subjects attained this parameter at the first trial of
the second session. Further comparison between those
who chose Diskus first and Turbhaler first was not pos-
sible because most of the subjects chose Diskus first.
However no trends were apparent between them.
Discussion
Inhalation therapy using DPIs is now the mainstay of
treatment of COPD and bronchial asthma. Since drug
dispersion and generation of fine particles are driven
by energy from inhaled flow through the DPI, inhal-
ation flow pattern including flow rate and timing of
peak flow impact its efficiency. Once dispersed from
the DPI, powdered drugs are propelled through the
airways and then precipitate in the large and small
bronchi making strength and depth of inhalation im-
portant. However, compared with instruction in
employing a DPI, systematic instruction in inhalation
flow through a DPI is not widely practiced. One rea-
son may be poor recognition of DPI-specific inhal-
ation patterns [1] by many DPI instructors, and this
may be partly due to lack of a convenient device to
visualize inhalation flow pattern. In-check and inhal-
ation trainers currently used are not satisfactory for
this purpose because these devices depict inhalation
flow rate at only one point in time. A few systems
visualizing the time course of inhalation flow rate
from a DPI have been reported [4–6]. However, all of
these systems are either complicated or expensive,
and thus are not suited to use in clinical practice.
Visual trainer, a low-cost and handy inhalation profile
analyzer, potentially solves these problems.
Threshold determination
Concerning the threshold value, we used a PIFR >
50 L/min because this value is recommended in use
Fig. 5 PIFR (a), F0.3 (b), TPF (c), and VI (d) of individual subjects in the first study. Gray lines indicate threshold values for individual parameters
Table 1 Inhalation parameters before the self-trainings (median,
75th and 25th percentiles)
Diskus Turbuhaler Difference
PIFR (L/min) 77.6, 89.3, 72.2 55.3, 64.5, 47.8 significant
VI (L) 1.63, 2.19, 1.40 1.11, 1.66, 0.95 significant
F0.3 (L/min) 64.9, 71.6, 58.3 47.2, 52.1, 39.1 significant
TPF (s) 0.69, 0.89, 0.57 0.74, 0.93, 0.61 ns
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of medium/high-resistance DPIs [1]. According to one
study on children well trained in DPI use [7], in
which the peak of drug dispersion from Diskus was
0.16 ± 0.14 s (mean ± SD) and that from Turbuhaler
was 0.19 ± 0.03 s, the PIFR should appear at around
0.16–0.19 s after onset of inhalation. In our previous
study using the inhalation trainers in healthy adults,
the TPF through Diskus was 0.44 ± 0.17 s and that
through Turbuhaler was 0.53 ± 0.23 s [8]. Thus, we
set the requirement of TPF as < 0.4 s. Although the
optimal VI from a DPI is not established, 80% vital
capacity is recommended in pMDI (pressurized
metered dose inhaler) use. However, favorable pul-
monary drug deposition (comparisons of 20, 50 and
80% vital capacities) [9] or drug absorption (func-
tional residual volume vs. total lung capacity) [10]
was reported with smaller inhalation volume. We set
1.0 L as a minimum requirement for VI. Inhaled
flows at 0.3 s after onset of inhalation (F0.3), which
represents the flow rate at termination of drug disper-
sion [7], was also measured.
The ISAM/ERS task force recommends a rapid and
forceful inhalation for reservoir or blister-type DPI [1].
Once drug has been dispersed from a DPI, inhalation flow
rate should be low to avoid precipitation in the upper air-
way. Studies on pMDI's suggest that a suitable flow after
drug dispersion is approximately 30 L/min [11]. Thus,
practically the best inhalation pattern for Diskus and Tur-
buhaler may be that shown as Fig. 4a [2], and this pattern
is exactly the same as that proposed by the ISAM/ERS
task force.
Pharmacists’ inhaled pattern
As shown in Figs. 5a and d, most of the pharmacists in-
haled forcefully (high PIFR) and deeply (large VI)
through both DPIs. The steepness of inhaled flow was
assessed by two parameters, TPF and F0.3. Most of the
subjects inhaled with an unsatisfactory TPF through
either DPI (Fig. 5c). Although TPF is a reasonable par-
ameter of flow steepness it is not a suitable index in
evaluation of the trapezoid pattern (see Fig. 4). Since
the trapezoid pattern was frequently seen in this
study, we adopted F0.3 as an additional parameter of
flow steepness. A satisfactory F0.3 was observed in 12
of 14 subjects in Diskus use but in only half of the
subjects with Turbuhaler use (Fig. 5b). Even though
high F0.3 is achieved, the trapezoid pattern is not
preferable because protracted high inhaled flow may
adversely affect both drug delivery and precipitation
in the pulmonary airways. Therefore, we concluded
that our subjects, who are regularly engaged in DPI
inhalation instruction, did not themselves inhale with
an appropriate flow pattern.
Effects of training with visual feedback
Steep increase in inhalation flow has a marked effect on
drug dispersion [12] as well as fine particle generation
from a DPI [13]. Unfortunately, many of our subjects
failed to achieve sufficiently rapid inhalation in terms of
TPF and F0.3. This finding is not surprising because cur-
rently available devices such as In-Check or trainer
whistles do not show flow trajectory. Al-Showair et al.
[14] have reported that an optimal inhalational flow
Fig. 6 Number of subjects who fulfilled the criteria at each trial. a; subject number who achieved all three criteria. b; those who reached PIFR
threshold. c; those who reached TPF threshold. d; those who reached VI threshold. In the 1st session, subjects started the inhalation trial with
either Diskus or Turbuhaler. In the 2nd session they selected the other DPI
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pattern was not achieved following verbal instruction,
and we also confirmed this [3]. Furthermore, even after
describing an optimal flow pattern, only 20% of the sub-
jects in the present study achieved a satisfactory pattern
at the first trial. Thus, currently available techniques in-
cluding verbal instructions, flow trainer devices, and de-
scription of optimal flow are limited. In contrast, after
self-training with Visual Trainer TPFs decreased remark-
ably. Since drug dispersion occurs at very early inhal-
ation, early development of PIFR augments inhalation
efficiency. As has been reported, some maneuvers aug-
ment inhalation depth and strength [15] but no strategy
for achieving rapid inhalation has been proposed.
Although our study had no control group, the results
suggest that self-training with visual feedback is a strong
tool to resolve this problem.
Once a subject had achieved an optimal flow pattern
using one DPI, many subjects inhaled optimally through
the other DPI (Fig. 6a). This occurred whether the DPIs
were changed from those with medium/high to low
resistance or vice versa. This suggests that, when the
type of DPI is changed, detailed instruction in flow
pattern is not required in well-trained patients.
Usefulness of visual trainer
With regard to the Visual Trainer in this study, we were
able to use 5 devices concurrently in the 2nd trial owing
to their cheap and handy attributes. This enabled the
collection of data in only one day while all the pharma-
cists were engaged in their hospital duties. Short-term
data collection might also preclude information ex-
change among the subjects who, in the self- training
study, could have impacted the results. We have re-
ported that patients regularly using DPIs do not always
inhale with adequate flow patterns [2].The present
results portend the effectiveness of Visual Trainer in
training such patients.
Conclusion
Visualization of the inhalation flow pattern facilitates the
learning of proper inhalation technique through a DPI.
An optimal inhalation pattern can be easily achieved by
self-training when the inhalation flow pattern is
displayed.
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